Clinical Trial Update: Immunogenicity, Reactogenicity and Safety Study of Two Different Formulations of GSK Biologicals' Human Rotavirus Vaccine, Rotarix, in Healthy Infants [Phase 3]

View source ↗

Summary

Phase 3 immunogenicity, reactogenicity and safety study comparing two Rotarix formulations in healthy infants has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rotavirus Infection

Drugs mentioned

• Rotarix (Rotavirus vaccine (live attenuated))

Snippet

Sponsor: GlaxoSmithKline | Conditions: Rotavirus | Phase 3 | Status: COMPLETED | Results posted: 2020-12-09